Nkarta presents data on NK cell based combination therapies

Nkarta announced the presentation of two preclinical data abstracts focused on its natural killer, NK, cell pipeline and proprietary manufacturing technology at the Society for Immunotherapy of Cancer, SITC, 37th Annual Meeting and Pre-Conference Programs. "Our presentations at this year’s SITC meeting illustrate the inherent power and potential of donor-derived NK cells," said James Trager, PhD, Chief Scientific Officer of Nkarta. "Nkarta’s research team has shown that our manufacturing platform technology can expand NK cells by well over a billion-fold, while maintaining their integrity and potency. These findings could prospectively allow us to derive our CAR NK products from a very limited set of stringently selected donors. In a second study, the team has also further built on the considerable potency of our CD19-directed CAR NK candidate, NKX019."